Clinical trials: Targeted Therapy, open to volunteers
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Internalizing Disorders, Substance Use Disorders
Family Support Protocol for Adolescent Internalizing Disorders
This R34 will develop and test an adjunctive treatment protocol for addressing co-occurring internalizing disorders among adolescents enrolled in usual care for substance use problems.
- Trial name
- Fam-AID (NCT06413979)
- Testing
- Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID)
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2.
- Conditions
- Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication
- Trial name
- NCT05388682
- Testing
- Percutaneous transluminal pulmonary angioplasty
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Fibrillation, Atrial
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
- Trial name
- NOAC (NCT06874894)
- Where
- 2 sites in South Korea
- Volunteers
- 1,021 people
- Sponsor
- Chung-Ang University Hospital
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
- Trial name
- NCT06355739
- Testing
- CAR T cell injection
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhu Xiaofan
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital
Cutaneous Metastatic Melanoma
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
This device phase I/II, first in human, early feasibility study (EFS), open-label, single-arm trial aims to evaluate the safety, tolerability, and preliminary efficacy of Gold Nanorod (GNR)-enabled sub-ablative targeted…
- Trial name
- NCT06870994
- Testing
- Targeted Hyperthermia Therapy
- Volunteers
- 10 people
- Sponsor
- Sona Nanotech Inc
Leukemia, Lymphoma
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
PACMAN is a phase I/II single arm, open-label, multi-center study evaluating the safety of human CD19 CAR-T (huCAR19) produced locally using the Miltenyi Prodigy in children, adolescents and young adults with relapsed/refractory…
- Trial name
- PACMAN (NCT07020260)
- Testing
- CAR T-cell and Cellular Therapies
- Where
- 2 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
International Leukemia Target Board
The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team…
- Trial name
- iLTB (NCT05270096)
- Testing
- Advice
- Where
- 7 sites in Belgium, Denmark and 5 more
- Volunteers
- 600 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Treatment Outcome
Lubinus SPII Hip Stem Target Trial Emulation
The research questions this study aims to answer are as follows: Primary research question: "Do primary total hip arthroplasties for patients with OA, hip fracture or osteonecrosis with the 150mm Lubinus SPII hip stem have better…
- Trial name
- LARGE (NCT06367829)
- Testing
- Lubinus SPII hip stem 130mm, Lubinus SPII hip stem 150mm
- Where
- Netherlands
- Volunteers
- 110,000 people
- Sponsor
- JointResearch
Functional Gastrointestinal Disorders (FGIDs), Cyclic Vomiting Syndrome
Autonomic Reactivity and Personalized Neurostimulation
Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc).
- Conditions
- Functional Gastrointestinal Disorders (FGIDs), Cyclic Vomiting Syndrome, Functional Dyspepsia, Dysautonomia
- Trial name
- NCT06863207
- Testing
- Percutaneous electrical nerve field stimulation, Hypnotherapy
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Relapsed / Refractory Osteosarcoma
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma.
- Trial name
- NCT07357519
- Testing
- LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Lantheus Medical Imaging
Insomnia, Suicidal Ideation
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
This study will test the effectiveness of a sleep-related primary suicide prevention program entitled TAILOR (Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior), which includes specific behavior-change…
- Conditions
- Insomnia, Suicidal Ideation, Suicide, Attempted
- Trial name
- TAILOR (NCT05390918)
- Testing
- TAILOR, Enhanced Usual Care
- Where
- United States
- Volunteers
- 235 people
- Sponsor
- Jeff Bridge
Reducing Tuberculosis Incidence
DeMONSTRATE-TB Study in Ethiopia
Ending the TB epidemic by 2035 in Ethiopia would be possible if TB notification declines by an annual factor of at least 15% from the current notification rate of 132 per 100,000 population.
- Trial name
- NCT06719193
- Testing
- Enhanced community-wide TB intervention, Routine TB program activities
- Where
- 2 sites in Ethiopia
- Volunteers
- 131,438 people, healthy volunteers welcome
- Sponsor
- Management Sciences for Health
DMG, DIPG
Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for Diffuse Midline Glioma (DMG), an aggressive brain tumor with a very poor prognosis - an average one-year overall survival.
- Trial name
- LIFT (NCT07796061)
- Testing
- TAA-T Cell, BBB Disruption
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Children's National Research Institute
B Cell Lymphoma (BCL)
Multi-CAR-T Cells Targeting B Cell Lymphomas
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and…
- Trial name
- NCT04429438
- Testing
- 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Depression in Adolescence, Delayed Sleep Phase
Better Sleep Study
The overall aim of this proposal is a confirmatory efficacy trial sufficiently powered and designed to test the hypothesis that improving the relationship between biological circadian timing and waketime, a novel modifiable…
- Trial name
- NCT06139861
- Testing
- TranS-C, Psychoeducation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Children's Hospital Los Angeles
Papillary Thyroid Cancer, Pediatric Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females.
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT05024929
- Testing
- Whole body scan
- Where
- 9 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
PSMA Positive Tumors or Tumor Tissues
PSMA-specific CAR-T Cell Therapy
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor.
- Trial name
- NCT04429451
- Testing
- 4SCAR-PSMA T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Non-progressive Congenital Ataxia, Ataxic Cerebral Palsy
ARTEMIS - The ARTEMIS Cohort
This multinational European observational clinical study focuses on non-progressive congenital ataxia (NPCA), a very rare early-onset neurological condition also within the cerebral palsy (CP) concept as ataxic CP.
- Trial name
- ARTEMIS (NCT07421219)
- Where
- 7 sites in Belgium, Denmark and 5 more
- Volunteers
- 50 people
- Sponsor
- Vastra Gotaland Region